HEMATOLOGY MCQ – Exercise 22

The multiple choice questions in this online test paper focuses on HEMATOLOGY MCQ. If you are looking for self evaluation of your PG Medical entrance exam preparation then this online HEMATOLOGY MCQ Test Paper will help you to evaluate your exam preparation.

Instruction for REPRODUCTIVE BIOLOGY/ REPRODUCTIVE MEDICINE / INFERTILITY MCQs:

1- This online MCQ practice test paper contains 30 questions.
2- Each question in this online practice test paper have four options and only 1 option is correct.
3- You can view the answers of this practice test paper after submitting the practice test paper.
Note: The answers mentioned at the end of practice test are the best suitable option as per our knowledge. Users shall cross-check the answers with their textbooks.

Q 1. proto-oncogene c-kit is expressed in

GI Stromal tumors

mast cell tumors

neuroblastoma

all of the above

Q 2. treatment of CML with imatinib recommended for

1 year

3 year

5 year

life long

Q 3. Reed-Sternberg cells seen in

infectious nucleosis

B and T cell lymphoma

melanomas

all of the above

Q 4. multiple myeloma is also called as

Kahler’s disease

Strohl’s disease

Kayle’s disease

Migasha disease

Q 5. multiple myeloma arises from

post germinal center B cell

post germinal center T cel

pre germinal center B cell

pre germinal center T cell

Q 6. nucleus in Reed-Sternberg cell is also called as

Owl eye appearance

spectacle appearance

Ghost appearance

Moon appearance

Q 7. protein kinase enzyme function is to transfer

phosphate from ATP to specific amino acids

adenosine from ATP to specific amino acids

phosphate and adenosine from ATP to specific amino acids

none of the above

Q 8. true regarding Hodgkins disease

disease not increasing in frequency

most patients present with palpable lymphadenopathy

subdiaphragmatic presentation is unusual

all of the above

Q 9. in CML therapy which of the following does not induce cytogenetic remission

imatinib mesylate

IFN-α

hydroxyurea

all of the above

Q 10. imatinib has effective activity against

CML

GIST

CMML

all of the above

Q 11. true regarding plasma cell disorders

monoclonal neoplasms

progenitor in B lymphocyte lineage

manifest clinically by expansion of neoplastic cells

all of the above

Q 12. following are subfamilies of protein kinases

protein serine –threonine kinases

protein tyrosine kinases

both of above

none of the above

Q 13. tyrosine kinase inhibited by imatinib is

c-kit

epidermal growth factor receptor FLT1

epidermal growth factor receptor FLT3

all of the above

Q 14. true regarding imatinib mesylate is

administered orally

dose is 400 mg/day

most common hematologic side effect is myelosuppression

all of the above

Q 15. not a plasma cell disorder

multiple myeloma

waldenstorm’s disease

primary amyloidosis

light chain disease

Q 16. drugs effective in treatment of CML

imatinib mesylate

IFN-α

hydroxyurea

all of the above

Q 17. true regarding classic Hodgkin’s disease

bimodal age distribution

one peak at 10-35 years of age

second peak in late life

all of the above

Q 18. most patients of Hodgkin’s disease have

mixed cellularity Hodgkin’s disease

nodular sclerosing Hodgkin’s disease

lymphocyte predominant Hodgkin’s disease

lymphocyte depleted Hodgkin’s disease

Q 19. chemotherapy regimens used in Hodgkin’s disease

ABVD

MOPP

BEACOPP

all of the above

Q 20. unusual manifestations of Hodgkin’s disease include

erythema nodosum

nephritic syndrome

hypercalcemia

all of the above

Q 21. Hodgkin’s disease is related to

neoplastic cells of B cell origin

polyclonal inflammatory infiltrate

monoclonal antibody Ki-1 reactivity to RS cell

all of the above

Q 22. CML with T315l mutation is resistance to

imatinib

nilotinib

dasatinib

all of the above

Q 23. heavy chain isotype of immunoglobulin molecule include all except

Q 24. in CML therapy which of the following does not induce rapid hematologic response

imatinib mesylate

IFN-α

hydroxyurea

all of the above

Q 25. Imatinib dose which is ineffective and may lead to development of resistance

<300 mg/day

<400 mg/day

<500 mg/day

<600 mg/day

Q 26. protein kinases includes

BCR-ABL

protein kinase C

epidermal growth factor receptor

all of the above

Q 27. following is mechanism of resistance to imatinib

gene amplification

mutations at the kinase site

enhanced expression of multidrug exporter proteins

all of the above

Q 28. diameter of Reed-Sternberg cells

5-10 µm

8-16 µm

12-20 µm

20-60 µm

Q 29. imatinib mesylate is most effective in

chronic phase CML

accelerated phase CML

blast crisis phase CML

all of the above

Q 30. imatinib mesylate is inhibitor of

ABL, ABL related gene products

c-kit

PDGF receptor (PDGFR)

all of the above

HEMATOLOGY MCQ – Exercise 22

pgmedmin

Recent Posts

Categories

HEMATOLOGY MCQ – Exercise 22

pgmedmin

Popular Tags

Recent Posts

Categories